Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 3/20 | 0.48 |
| ▸ | MET | P08581 | 3/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 12/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | STK10 | O94804 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4669926 | 0.87 | SMN1; SMN2 (0.53) | AXLMETPDGFRAFGFR2MAPT | |
| SCHEMBL4669699 | 0.87 | PDGFRA (0.53) | AXLMETPDGFRAFGFR2KDR | |
| SCHEMBL4669705 | 0.85 | KDR (0.67) | AXLMETPDGFRAFGFR2KDR | |
| SCHEMBL4671729 | 0.84 | FGFR2 (0.56) | AXLMETPDGFRAFGFR2MAPT | |
| SCHEMBL4669729 | 0.84 | PDGFRA (0.52) | CYP2C9AXLMETPDGFRAFGFR2 | |
| SCHEMBL5203290 | 0.79 | PDGFRA (0.70) | AXLMETPDGFRAFGFR2KDR | |
| SCHEMBL5201774 | 0.78 | PDGFRA (0.62) | AXLMETPDGFRAFGFR2KDR | |
| SCHEMBL5205605 | 0.78 | PDGFRA (0.72) | AXLMETPDGFRAFGFR2KDR | |
| SCHEMBL5202707 | 0.77 | PDGFRA (0.76) | PDGFRAKDR | |
| SCHEMBL5203378 | 0.76 | KDR (0.57) | AXLMETPDGFRAFGFR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1652847-B1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN PHARMA KK (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1652847-A1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-03 | — | — | EP | claimed |
| EP-1652847-B1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN PHARMA KK (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-7211587-B2 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (KR) | 2007-05-01 | — | — | US | disclosed |
| EP-1652847-A1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6821987-B2 | 4-SUBSTITUTED BY AZOLYLUREIDO-PHENOXY, OR PHENYLTHIO; ANTITUMOR AGENTS; TREATING DIABETIC RETINOPATHY, CHRONIC RHEUMATISM, PSORIASIS, ATHEROSCLEROSIS, | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1382604-A1 | QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | CYP2C9 346/4885CYP2C19 1388/4885AXL 1464/4885 |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | CYP2C9 346/4885CYP2C19 1388/4885AXL 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.